Tris Pharma Inc.

Mar 17, 2020

Quillivant XR®, QuilliChew ER® and Dyanavel® XR are 100% Made in the U.S.A. and Remain Consistently Supplied During COVID-19 Pandemic

Jan 17, 2020

APSARD and Tris Pharma Announce the Inaugural Tris Research Award in ADHD

Nov 07, 2019

Tris Pharma to Present Two Posters for Amphetamine Extended-Release Tablet at the 2019 Neuroscience Education Institute (NEI) Congress

Oct 30, 2019

Tris Pharma Adds Seasoned Attorney to its Senior Leadership Team

Sep 04, 2019

Tris Pharma Strengthens Its Branded Commercial Leadership Team

Aug 14, 2019

Tris Pharma Chief Medical Officer Elected to the American Psychiatric Association Assembly Executive Committee

Jan 17, 2019

Tris Pharma to Present Three Posters Covering Data on Dyanavel® XR and Tris' LiquiXR® Technology at the 2019 APSARD Annual Meeting

Dec 05, 2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Nov 12, 2018

Tris Pharma Presents Clinical Data for DYANAVEL® XR (amphetamine) at the 2018 Neuroscience Education Institute (NEI) Congress

Oct 10, 2018

Tris Pharma Announces Hiring of Chief Commercial Officer

Sep 25, 2018

Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals

Aug 27, 2018

Tris Pharma Announces Hiring of New Vice President of Quality & Compliance